Dilip Shanghvi didn’t begin in a lab or inherit a pharmaceutical empire. In the late 1970s, he helped his father distribute generic medicines as a wholesale distributor in Kolkata. Decades later, he sits atop Sun Pharmaceutical Industries Ltd., the company that turned opportunistic acquisitions and painstaking regulatory work into predictable engines of growth. The lesson is simple and ruthless: buy problems cheaply, fix them methodically, and extract long-term value.
Sun Pharma’s playbook is repeatable and has been executed with precision: distressed asset → acquisition during regulatory/financial crisis → operational remediation → market consolidation and cash generation. Four landmark deals show how the strategy evolved from simple generics to specialized therapies, culminating in an unprecedented global move.
Free Membership Required
You must be a Free member to access this content.
